A group of bipartisan senators introduced a plan to streamline the FDA‘s regulation that would speed up the process of taking innovations to the market and encourage innovation. The bill would also focus on restoring balance to the conflict of interest requirements within the FDA. With the rules in place now to reduce industry ties in advisory committees, complications and delays can arise. The bill aims to ease strict rules on conflict of interest that can cause delays.
To read the full article from Policy and Medicine, go here or you can read “Medical Device Regulatory Improvement Act” in its entirety.